During its latest fiscal year, BD reported its revenues dipping 1.4 percent as it made $19.1 billion in 2021 and raked in $18.9 billion in 2022.
The company attributed part of the loss to less demand for its COVID-19 diagnostic tests. Among its three main segments — medical, life sciences and interventional — BD’s life sciences sales fell 16.3 percent compared to last year’s figures because of dwindling demand for COVID-19 tests.
BD whittled its 2023 projected earnings for the tests to be between $125 million and $175 million — a sharp dropoff from 2022’s sales, which were $511 million.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
